Toll-like receptor 4 antagonists - Pipeline Insight, 2022
This report can be delivered to the clients within 48 Hours
DelveInsight’s, “Toll-Like Receptor 4 (TLR-4) Agonist - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Toll-Like Receptor 4 (TLR-4) Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Toll-Like Receptor 4 (TLR-4) Agonist: Overview
The activation of toll-like receptor 4 (TLR4) has been proposed to have a major influence on the inflammatory signalling pathways of the intestinal tract. Inhibition of TLR4 has been postulated as an effective way to treat intestinal inflammation. However, there are a limited number of studies looking into the potential of TLR4 antagonism as a therapeutic approach for intestinal inflammation.
Toll-like receptors (TLRs) are type 1 transmembrane proteins belonging to the wider family of pattern recognition receptors, and are responsible for the recognition of a variety of molecular signals, including endogenous damage and pathogen-associated signals, damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs), respectively. TLR4 is an intra- and extracellular receptor expressed on endosomes and cytoplasmic membranes, which recognizes PAMPs (flagellin and LPS) and DAMPS (calprotectin, S100A8/9 HMGB1 and HSP70) through its co-receptors MD2 and CD14.
Targeting TLR4 could represent a potential approach to regulate immune responses and treat inflammation. However, any potential therapeutic agent must be able to block the harmful effects of TLR4 activation without negatively affecting the host’s defence functions. Anti-TLR4 therapies present a promising alternative for future innovative treatments for both inflammatory bowel disease and intestinal mucositis.
Report Highlights
This segment of the Toll-Like Receptor 4 (TLR-4) Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Toll-Like Receptor 4 (TLR-4) Agonist Emerging Drugs
It is currently in Phase III stage of development and is being developed by Eisai.
It is currently in Phase II stage of development and is being developed by Akaza Bioscience.
Further product details are provided in the report……..
Toll-Like Receptor 4 (TLR-4) Agonist: Therapeutic Assessment
This segment of the report provides insights about the different Toll-Like Receptor 4 (TLR-4) Agonist drugs segregated based on following parameters that define the scope of the report, such as:
Toll-Like Receptor 4 (TLR-4) Agonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Toll-Like Receptor 4 (TLR-4) Agonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Toll-Like Receptor 4 (TLR-4) Agonist drugs.
Toll-Like Receptor 4 (TLR-4) Agonist Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “Toll-Like Receptor 4 (TLR-4) Agonist - Pipeline Insight, 2022” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Toll-Like Receptor 4 (TLR-4) Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Toll-Like Receptor 4 (TLR-4) Agonist: Overview
The activation of toll-like receptor 4 (TLR4) has been proposed to have a major influence on the inflammatory signalling pathways of the intestinal tract. Inhibition of TLR4 has been postulated as an effective way to treat intestinal inflammation. However, there are a limited number of studies looking into the potential of TLR4 antagonism as a therapeutic approach for intestinal inflammation.
Toll-like receptors (TLRs) are type 1 transmembrane proteins belonging to the wider family of pattern recognition receptors, and are responsible for the recognition of a variety of molecular signals, including endogenous damage and pathogen-associated signals, damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs), respectively. TLR4 is an intra- and extracellular receptor expressed on endosomes and cytoplasmic membranes, which recognizes PAMPs (flagellin and LPS) and DAMPS (calprotectin, S100A8/9 HMGB1 and HSP70) through its co-receptors MD2 and CD14.
Targeting TLR4 could represent a potential approach to regulate immune responses and treat inflammation. However, any potential therapeutic agent must be able to block the harmful effects of TLR4 activation without negatively affecting the host’s defence functions. Anti-TLR4 therapies present a promising alternative for future innovative treatments for both inflammatory bowel disease and intestinal mucositis.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Toll-Like Receptor 4 (TLR-4) Agonist R&D. The therapies under development are focused on novel approaches for Toll-Like Receptor 4 (TLR-4) Agonist.
This segment of the Toll-Like Receptor 4 (TLR-4) Agonist report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Toll-Like Receptor 4 (TLR-4) Agonist Emerging Drugs
- E-5564: Eisai
It is currently in Phase III stage of development and is being developed by Eisai.
- TAK-242: Akaza Bioscience
It is currently in Phase II stage of development and is being developed by Akaza Bioscience.
Further product details are provided in the report……..
Toll-Like Receptor 4 (TLR-4) Agonist: Therapeutic Assessment
This segment of the report provides insights about the different Toll-Like Receptor 4 (TLR-4) Agonist drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on Toll-Like Receptor 4 (TLR-4) Agonist
- Phases
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
Toll-Like Receptor 4 (TLR-4) Agonist: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Toll-Like Receptor 4 (TLR-4) Agonist therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Toll-Like Receptor 4 (TLR-4) Agonist drugs.
Toll-Like Receptor 4 (TLR-4) Agonist Report Insights
- Toll-Like Receptor 4 (TLR-4) Agonist Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing Toll-Like Receptor 4 (TLR-4) Agonist drugs?
- How many Toll-Like Receptor 4 (TLR-4) Agonist drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for Toll-Like Receptor 4 (TLR-4) Agonist?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Toll-Like Receptor 4 (TLR-4) Agonist therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Toll-Like Receptor 4 (TLR-4) Agonist and their status?
- What are the key designations that have been granted to the emerging drugs?
- Eisai
- Akaza Bioscience
- OPNT-003
- GeNeuro
- MN-166 (ibudilast)
- Orexo
- E5564
- TAK-242
- OPNT-003
- Temelimab
- MediciNova
- OX125
Introduction
Executive Summary
Toll-Like Receptor 4 (TLR-4) Agonist: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Toll-Like Receptor 4 (TLR-4) Agonist– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Toll-Like Receptor 4 (TLR-4) Agonist companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Toll-Like Receptor 4 (TLR-4) Agonist Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
E5564: Eisai
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
TAK-242: Akaza Bioscience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
OX125: Orexo
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Toll-Like Receptor 4 (TLR-4) Agonist Key Companies
Toll-Like Receptor 4 (TLR-4) Agonist Key Products
Toll-Like Receptor 4 (TLR-4) Agonist- Unmet Needs
Toll-Like Receptor 4 (TLR-4) Agonist- Market Drivers and Barriers
Toll-Like Receptor 4 (TLR-4) Agonist- Future Perspectives and Conclusion
Toll-Like Receptor 4 (TLR-4) Agonist Analyst Views
Toll-Like Receptor 4 (TLR-4) Agonist Key Companies
Appendix
Executive Summary
Toll-Like Receptor 4 (TLR-4) Agonist: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Toll-Like Receptor 4 (TLR-4) Agonist– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Toll-Like Receptor 4 (TLR-4) Agonist companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Toll-Like Receptor 4 (TLR-4) Agonist Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
E5564: Eisai
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
TAK-242: Akaza Bioscience
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
OX125: Orexo
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Comparative Analysis
Drug Name: Company Name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Toll-Like Receptor 4 (TLR-4) Agonist Key Companies
Toll-Like Receptor 4 (TLR-4) Agonist Key Products
Toll-Like Receptor 4 (TLR-4) Agonist- Unmet Needs
Toll-Like Receptor 4 (TLR-4) Agonist- Market Drivers and Barriers
Toll-Like Receptor 4 (TLR-4) Agonist- Future Perspectives and Conclusion
Toll-Like Receptor 4 (TLR-4) Agonist Analyst Views
Toll-Like Receptor 4 (TLR-4) Agonist Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Toll-like receptor 4 antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Toll-like receptor 4 antagonists
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Toll-like receptor 4 antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Toll-like receptor 4 antagonists
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
